Creo Medical Group PLC CEO Craig Gulliford takes Proactive's Stephen Gunnion through the company’s progress with its MicroBlate Flex technology in treating lung cancer. The discussion highlighted the first patient treated in the Ablate and Resect study. Gulliford explained, “This key part of this study is the ability to ablate a piece of diseased tissue immediately prior to the tissue being surgically removed.”

This approach helps clinicians understand precisely how the ablation affects tumour tissue under microscopic analysis. He also outlined how the study complements the existing Ablate and Follow program, which tracks patients over time to assess safety and early indicators of efficacy.

Gulliford described collaboration with Intuitive and the use of the Ion robot as critical to accelerating the clinical and commercial rollout of MicroBlate Flex. The company aims to complete both the Ablate and Reset and Ablate and Follow studies during the year. Initial sales of MicroBlate Flex have already begun, supporting Creo Medical's efforts to establish a strong clinical evidence base and grow adoption in the pulmonary cancer treatment market.

For more interviews and updates, visit Proactive’s YouTube channel, give this video a like, subscribe, and enable notifications so you never miss future content.

#CreoMedical #MicroBlateFlex #LungCancerTreatment #MedicalDevices #CancerResearch #IntuitiveSurgery #IonRobot #ClinicalTrials #HealthTech #PulmonaryOncology

Ver todos los episodios